Company intelligence / Profile preview
Xytis
Irvine, California, United Statesxytis.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Xytis developed small molecule therapeutics for central nervous system disorders. Its lead programs included Anatibant (XY2405), a bradykinin B2 antagonist in Phase 2 trials for traumatic brain injury with Fast Track and Orphan Drug status in the US/EU, and Neboglamine (XY2401), targeting cognitive/negative symptoms of schizophrenia in early clinical studies. Both compounds showed good safety/tolerability profiles in initial trials. The company also had preclinical allosteric modulators of GABA-A and nicotinic acetylcholine receptors.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical partnerships disclosed; some partnering interest noted for preclinical programs as per management statements
Beyond the preview
Go deeper on Xytis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xytis.